NCT00294164View on ClinicalTrials.gov

Safety and Efficacy Trial of Serostim® in the Treatment of Subjects With Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

245

Participants

Timeline

Start Date

March 31, 2001

Primary Completion Date

May 31, 2002

Study Completion Date

May 31, 2002

Conditions
Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)Human Immunodeficiency Virus Infections
Interventions
DRUG

Serostim®

Serostim® will be administered subcutaneously (daily or given on alternate days with matched placebo), at a dose based on body weight measured at Baseline, with a maximum daily dose of 4 mg up to Week 24.

DRUG

Placebo

Matching placebo will be administered subcutaneously (daily or given on alternate days with Serostim®), up to Week 24.

Sponsors

Lead Sponsor

EMD Serono
All Listed Sponsors
lead

EMD Serono

INDUSTRY

NCT00294164 - Safety and Efficacy Trial of Serostim® in the Treatment of Subjects With Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS) | Biotech Hunter | Biotech Hunter